Blood sampling from healthy, adult volunteers for isolation of peripheral blood mononuclear cells (PBMCs) for in vitro analysis of the human immune response towards Nanobodies. Not Applicable
Conditions
Interventions
Blood sampling (up to 450 ml). Nothing is administered.
Sponsors
Vrije Universiteit Brussel
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Good general health 2. Aged 18-65
Exclusion criteria
Exclusion criteria: 1. Pregnant (in case of doubt, a test will be taken) or envisages a pregnancy in the near future 2. History of significant inconvenience with blood sampling 3. High risk for HIV, HBV or HCV 4. Has received blood or blood products in the last 6 months 5. Has received any therapeutic treatment that influences the immune system 6. Presence of acute or chronic infection or disease 7. Currently taking drugs, except for contraceptives 8. Associated with the current study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T cell proliferation and differentiation in vitro as surrogate marker for the in vivo development of anti-drug antibody formation, measured 1-2 weeks after blood sampling. | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunogenic regions of the Nanobodies are identified and mutated, and the resulting new Nanobodies are tested once again for immunogenicity. Measurements are carried out 2.5 years after blood sampling. | — |
Countries
Belgium
Outcome results
None listed